Sponsor
Fujian Cancer Hospital
Clinical research sponsor
How to interpret these research links
Connected source recordsThe exact organization name Fujian Cancer Hospital appears in 37 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
37 shownPre-Treatment DCE-MRI AI Models Predict Neoadjuvant Chemotherapy Response in HR+/HER2- Breast CancerNCT07702708 · lead sponsor · 2026-06-01
RECRUITINGEfficacy and Safety of Dalpiciclib Combined With Endocrine Adjuvant Therapy for Early HR +/HER2- Breast Cancer: a Multicenter, Prospective Clinical StudyNCT07581834 · lead sponsor · 2026-01-21
RECRUITINGPostoperative Radiotherapy for Postoperative N2 Metastases of NSCLC in the Immunotherapy Era (Phase II)NCT07320105 · lead sponsor · 2026-01-15
RECRUITINGDalpiciclib Combined With Endocrine Therapy and Metronomic Capecitabine vs Dalpiciclib Combined With Endocrine Therapy for First-line TreatmentNCT07467330 · lead sponsor · 2025-11-15
RECRUITINGTrastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast CancerNCT07766772 · lead sponsor · 2026-09-30
NOT_YET_RECRUITINGKumorixilib Plus Capecitabine and Letrozole for Neoadjuvant Treatment of HR-Positive HER2-Negative Breast CancerNCT07691333 · lead sponsor · 2026-06-30
NOT_YET_RECRUITINGBronchial Artery Chemoembolization (BACE) Combination Therapy for Advanced NSCLCNCT07738367 · lead sponsor · 2026-04-09
ENROLLING_BY_INVITATIONHetrombopag for the Prevention of ADC-Induced Thrombocytopenia in Breast Cancer: An Exploratory, Dual-Cohort, Phase 2 StudyNCT07243418 · lead sponsor · 2025-11-30
NOT_YET_RECRUITINGA Study on the First-line Treatment of Small Cell Lung Cancer With Adebrelimab and Vunakizumab and ChemotherapyNCT07069270 · lead sponsor · 2025-09-01
NOT_YET_RECRUITINGDalpiciclib as Adjuvant Therapy for HR-positive/HER2-negative Early-stage PatientsNCT07101159 · lead sponsor · 2025-09-01
NOT_YET_RECRUITINGA Study of Adebelimab Combined With Chemotherapy as a First-line Treatment Sequential Treatment for Extensive-stage Small Cell Lung CancerNCT06614621 · lead sponsor · 2025-02-01
NOT_YET_RECRUITINGA Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung CancerNCT06786312 · lead sponsor · 2025-01-25
NOT_YET_RECRUITINGSMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)NCT06208033 · lead sponsor · 2024-01-10
UNKNOWNPARP Inhibitor CVL218 in Combination Therapy for Patients With Advanced Solid TumorsNCT06078670 · lead sponsor · 2023-10-10
UNKNOWNSurufatinib Combined With Serplulimab Plus Chemotherapy in the Treatment of Extensive-stage Small Cell Lung CancerNCT05882630 · lead sponsor · 2023-06-01
UNKNOWNOncorine (H101) Combined With Tislelizumab and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung CancerNCT06136910 · lead sponsor · 2023-05-09
UNKNOWNA Study of Eribulin-Based Regimen Versus Other Chemotherpy in Triple-Negative Metastatic Breast Cancer (ERI-Based-01).NCT05953909 · lead sponsor · 2023-02-01
UNKNOWNSerplulimab Combined With Anti-VEGF Antibody in Advanced Lung AdenocarcinomaNCT05675033 · lead sponsor · 2023-01-10
UNKNOWNSurufatinib Combined With Irinotecan as a Second-line Treatment for Small Cell Lung CancerNCT05595889 · lead sponsor · 2022-12-01
UNKNOWNthe Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug ChemotherapyNCT05497076 · lead sponsor · 2022-09-01
UNKNOWNTislelizumab as Cross-line Treatment for Advanced NSCLCNCT05192681 · lead sponsor · 2021-10-10
UNKNOWNApatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast CancerNCT05019690 · lead sponsor · 2021-10-01
UNKNOWNToripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line ChemotherapyNCT04613804 · lead sponsor · 2020-12-01
UNKNOWNPhase I Study of the Combination of Anlotinib With Pemetrexed or DocetaxelNCT03566576 · lead sponsor · 2018-07-01
UNKNOWNGefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR MutationNCT03486496 · lead sponsor · 2018-06-05
UNKNOWNAfatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell CarcinomaNCT03486509 · lead sponsor · 2018-04-01
UNKNOWNNext-generation Sequencing of Small Cell Lung Cancer to Identify Susceptibility Gene and to Assess TreatmentNCT03244904 · lead sponsor · 2017-11-01
UNKNOWNEGFR Mutation Positive NSCLC Patients With Gefitinib and ThalidomideNCT03341494 · lead sponsor · 2017-04-01
UNKNOWNThe Efficacy and Safety of Endostar Combined With Taxane-based Regimens for HER-2-negative MBC PatientsNCT02865304 · lead sponsor · 2016-12-01
UNKNOWNA Nationwide Multicenter, Single-arm, Retrospective Study of Delayed Endoscopic DTI-BR After Simple MastectomyNCT07257003 · collaborator · 2025-12-01
NOT_YET_RECRUITINGPosterior Extra-fascial RARP in Intermediate or High Risk Prostate CancerNCT06434649 · collaborator · 2025-11-01
ACTIVE_NOT_RECRUITINGPostbiotics Ameliorate Cachexia in Patients With Non-small-cell Lung CancerNCT07185308 · collaborator · 2025-11-01
NOT_YET_RECRUITINGStudy of Cadonilimab Combined With Bevacizumab and Chemotherapy for Advanced Nonsquamous Non-small Cell Lung Cancer Patients With Untreated Brain MetastasesNCT05812534 · collaborator · 2023-12-01
UNKNOWNTGRX-326 Chinese Phase II for Advanced Non-small Cell Lung Cancer (NSCLC)NCT05955391 · collaborator · 2023-01-18
ACTIVE_NOT_RECRUITINGPhase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination DeficiencyNCT05461690 · collaborator · 2022-09-01
UNKNOWNctDNA Analysis to Monitor the Risk of Progression After First-line Immunotherapy in Patients With Advanced NSCLCNCT05198154 · collaborator · 2022-01-24
ACTIVE_NOT_RECRUITINGRecombinant Human Endostatin Continued Pumping Into Vein Combining With CCRT in Unresectable Stage III NSCLCNCT01733589 · collaborator · 2012-11-01
COMPLETEDDrugs studied in this sponsor's trials
13 mapped RxNorm conceptsThese drug records are connected through ClinicalTrials.gov studies listing Fujian Cancer Hospital as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.
afatinib1
berberine1
capecitabine1
docetaxel1
etoposide Injection1
gefitinib1
irinotecan1
niraparib1
afatinib RxCUI 1430438 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
berberine RxCUI 1437 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
capecitabine RxCUI 194000 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
etoposide Injection RxCUI 1734339 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
gefitinib RxCUI 328134 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
irinotecan RxCUI 51499 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
niraparib RxCUI 1918231 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting
1 trial
pemetrexed RxCUI 68446 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
thalidomide RxCUI 10432 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
tislelizumab RxCUI 2677426 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
toripalimab Injection RxCUI 2669410 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
trastuzumab RxCUI 224905 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting
1 trial
Sponsor roles
lead sponsor29
collaborator8
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.